Pipeline

July 23, 2018

Company	Drug/Device	Medical Condition	Status
Blade Therapeutics	BLD-2660	debilitating fibrotic diseases	Phase I trial initiated
SOM Biotech	SOM3355	chorea movements associated with Huntington’s disease	Phase II trial initiated enrolling 30 subjects
Concentric Analgesics, Inc.	CA-008	post-surgical pain	Phase II trial initiated
Ironwood Pharmaceuticals, Inc.	linaclotide	irritable bowel syndrome with constipation (IBS-C)	Phase IIIb trial initiated enrolling 600 adult IBS-C subjects in the U.S.
RDD Pharma	RDD-0315	fecal incontinence in subjects with spinal cord injury	IND clearance granted by the FDA
MaxCyte	MCY-M11 (chimeric antigen receptor (CAR) therapeutic candidate)	solid tumors	IND clearance granted by the FDA
Stryker Corporation	Surpass Streamline Flow Diverter	unruptured large and giant wide neck intracranial aneurysms	PMA granted by the FDA
Astellas Pharma Inc. and Pfizer Inc.	XTANDI (enzalutamide)	castration-resistant prostate cancer, including men with non-metastatic CRPC	sNDA approval granted by the FDA
Adaptiiv	3D Bolus Software	cancer	510(k) clearance granted by the FDA
Zavation	Normandy VBR System (Cervical and Thoracolumbar Expandable Corpectomy Cage)	cervical spine (C2-C7) and thoracolumbar spine (T1-L5) for partial or total replacement of a diseased, collapsed, damaged or unstable vertebral body	510(k) clearance granted by the FDA
Quidel Corporation	Solana Bordetella Complete Molecular Diagnostic Assay	detection of Pertussis (whooping cough) Parapertussis Infections	510(k) clearance granted by the FDA
Genentech	TECENTRIQ (atezolizumab) in combination with Avastin (bevacizumab)	chronic lymphocytic leukemia	Breakthrough Therapy Designation granted by the FDA
Gamida Cell	NiCord	hematopoietic stem cell transplantation (HSCT)	Orphan Drug Designation granted by the FDA
Inozyme Pharma	INZ-701	ENPP1 Deficiency (GACI in infants and ARHR2 post-infancy)	Orphan Drug Designation granted by the FDA
Vallum Corporation	polyetheretherketone (PEEK) spinal interbody fusion device	spinal fusion	Clearance granted by the FDA
SIGA Technologies Inc. and U.S. Department of Health and Human Services’ BARDA	TPOXX (tecovirimat)	smallpox	Approval granted by the FDA
Janssen Pharmaceutical Companies of Johnson & Johnson	SYMTUZA	darunavir-based single-tablet regimen (STR) for the treatment of human immunodeficiency virus type 1 (HIV-1) in treatment-naïve and certain virologically suppressed adults	Approval granted by the FDA